Production has begun on the first batch of Novavax’s (Nasdaq: NVAX) COVID-19 vaccine candidate, under an agreement with a subsidiary of Fujifilm Corp (TYO: 4901).
The Japanese conglomerate’s biotech contract development and manufacturing organization (CDMO), FUJIFILM Diosynth Biotechnologies (FDB), is utilizing a site in North Carolina, USA.
Maryland, USA-based Novavax has agreed terms with FDB for the manufacture of the bulk drug substance for NVX-CoV2373, which was created using the firm’s recombinant nanoparticle technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze